← All organizations
Highest phase reached
Phase 4
First clinical trial
Mar 1, 2006Last known activity
Mar 20, 2024
Timeline
1990s
- Mar 28, 1998
Changi General Hospital— Founded
Drugs by trial phase (40 distinct, 33 trials)
Phase 4 (14 own, 0 via acquisition)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (7 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Adenoma
- Bacteremia
- Bacterial Infections
- Benign Paroxysmal Positional Vertigo
- Body Weight
- Cardio-Renal Syndrome
- Cognitive Dysfunction
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dizziness
- End Stage Liver Disease
- Fatty Liver
- Gastritis
- Healthcare-Associated Pneumonia
- Heart Arrest
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- HIV Infections
- Hyperaldosteronism
- Hypertension
- Infections
- Insulin Resistance
- Liver Cirrhosis
- Liver Diseases
- Non-alcoholic Fatty Liver Disease
- Pneumonia
- Pneumonia, Ventilator-Associated
- Stomach Neoplasms
- Stroke
- Syndrome
- Vertigo
- Weight Loss
Recent trials (50)
- NCT06636513OfficialN/AMar 20, 2024
- NCT06636513Lead sponsorN/AMar 20, 2024
- NCT06636513Sponsor investigatorN/AMar 20, 2024
- NCT05516628CollaboratorPhase 2Oct 31, 2022
- NCT05199324CollaboratorPhase 3Apr 1, 2022
- NCT04717102Overall official - principal investigatorPhase 4Apr 14, 2021
- NCT04717102Lead sponsorPhase 4Apr 14, 2021
- NCT04717102Reponsible party - principal investigatorPhase 4Apr 14, 2021
- NCT05083572Lead sponsorPhase 4Mar 10, 2021
- NCT05083572Overall official - principal investigatorPhase 4Mar 10, 2021
- NCT05083572Reponsible party - principal investigatorPhase 4Mar 10, 2021
- NCT04578470Lead sponsorPhase 2Nov 1, 2020
- NCT04775329Overall official - principal investigatorPhase 2/Phase 3Nov 1, 2020
- NCT04775329Lead sponsorPhase 2/Phase 3Nov 1, 2020
- NCT04457726CollaboratorPhase 1/Phase 2Jul 1, 2020
Details
- Founded
- Singapore, SG Mar 28, 1998
- Last known activity
- Mar 20, 2024